45 results on '"Salgia, Ravi"'
Search Results
2. Abstract 3535: Simultaneous inhibition of Axl and MerTK enhances anti-PDL1 efficacy and creates a pro-inflammatory tumor immune microenvironment in head and neck cancer
3. Abstract LB553: Empowering tobacco using cancer patient initiation of tobacco cessation by a personal pathway to success program during preoperative patient counseling: A feasibility study
4. Abstract 1489: MicroRNA-1 targets CXCR4/FOXM1/RRM2 axis regulating small cell lung cancer growth and metastasis
5. Abstract 5345: Novel approach to attenuate melanoma initiation and progression
6. Abstract 6397: Focal adhesion kinase (FAK) inhibition overcomes cisplatin resistance in head and neck squamous cell carcinoma (HNSCC)
7. Abstract 5279: HSP72 expression and suppression of resistance is associated with survival in EGFR mutated NSCLC
8. Abstract 2607: Integrin Beta4/Paxillin mediated chemoresistance in lung adenocarcinoma
9. Abstract 4173: 2′-Hydroxyflavanone inhibits RLIP and suppresses breast cancer cell proliferation and metastasis
10. Abstract 6329: Carfilzomib: A potential drug against cisplatin-resistant lung adenocarcinoma
11. Abstract 3300: Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
12. Abstract 5426: Genomic and immunohistochemical characterization of patients with advanced papillary renal cell carcinoma: Focus on exceptional responders
13. Abstract 6130: Zebrafish: A prominent tool for cancer drug screening and discovery
14. Abstract 2037: Association of molecular heterogeneity and actionable mutations with survival in lung cancer
15. Abstract B13: Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer
16. Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC)
17. Abstract 4361: Efficacy of MET inhibitors in NSCLC with CBL alterations
18. Abstract LB-239: Inhibition of MET/RON in lung cancer
19. Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab
20. AXL Mediates Resistance to Cetuximab Therapy
21. Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer
22. Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers
23. Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer
24. Abstract 2232: Overexpression of the mu opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth and metastasis
25. Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition
26. Abstract 2341: Functional analysis of paxillin mutations identified in lung cancer and malignant mesothelioma: Implications for cell migration/motility
27. Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies
28. Abstract 5136: Discovery of novel functional germline variations in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer
29. Abstract LB-124: RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
30. Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions
31. Abstract 2223: Screening for oncoviruses using next-generation sequencing
32. Abstract 2176: Vascular endothelial growth factor receptor-2 (VEGFR-2) gene variations in bronchioloalveolar cell carcinoma (BAC)
33. Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors
34. Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition
35. The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
36. Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
37. A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts
38. c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion
39. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
40. Expression of Siva-1 Protein or Its Putative Amphipathic Helical Region Enhances Cisplatin-Induced Apoptosis in Breast Cancer Cells: Effect of Elevated Levels of BCL-2
41. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer
42. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
43. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
44. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
45. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.